Fig. 3: pPGSs identify mechanisms for endophenotypes of psychotic disorders.
From: Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis
A Subjects were phenotyped on a range of psychological, clinical, and neurological measures. B Dopamine pPGS was associated with poorer global functioning and role functioning in psychosis subjects when controlling for diagnosis and overall SZ PGS. Only the association with global functioning passed FDR < 0.10. C Glutamate pPGS showed associations with poorer performance and reduced cortical activation in psychosis subjects during the AX-CPT cognitive control task when controlling for diagnosis and overall SZ PGS. Only the association with DLPFC β-values passed FDR < 0.10. D Treatment response showed a slight association with increased dopamine pPGS, though this did not pass FDR < 0.10. (Resp. = responder to treatment, non-resp. = non-responder to treatment).
